- Market Capitalization, $K 382,906
- Shares Outstanding, K 35,030
- Annual Sales, $ 0 K
- Annual Income, $ -96,710 K
- 60-Month Beta N/A
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 111.68
|Period||Period Low||Period High||Performance|
| || |
+4.46 (+68.95%)since 11/08/19
| || |
+3.18 (+41.04%)since 09/09/19
Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.
Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.
Companies in the news are: RARX, BBBY, PCG, MITO
Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.
--- If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license -
Stealth BioTherapeutics Corp (MITO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Stealth BioTherapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
--Grew Debt Investment Portfolio by $160.5 Million, Leading to Record Total Debt Investments of $1.91 Billion, at Cost
--Record FY2018 New Debt and Equity Commitments of $1.21 Billion, up 37.6% Year-over-Year